NK510 cell therapy for advanced lung cancer after immunotherapy
Treatments studied
Part of Cancer, Lungs & breathing clinical trials.
This trial tests a new natural killer (NK) cell therapy, NK510, for people with advanced non-small cell lung cancer who have already tried immunotherapy and it stopped working. The goal is to see if NK510 is safe and can shrink tumors or slow the cancer's growth.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 or older.
- You must have advanced non-small cell lung cancer (stage III or IV) that cannot be removed by surgery or treated with radiation.
- Your cancer must not have certain gene changes (EGFR, ROS1, ALK), unless you have a different group in the trial.
- You must have tried at least 4 rounds of an immunotherapy drug (PD-1 or PD-L1 blocker) with or without chemotherapy, and your cancer got worse.
- You must have at least one tumor that can be measured on a CT or MRI scan.
- You must be in generally good health (ECOG score 0-2) and expected to live at least 3 more months.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new combination of two drugs—an immunotherapy called tislelizumab and an experimental antibody-drug conjugate called SYS6010—for people with advanced non-small cell lung cancer who have already tried immunotherapy and their cancer continued to grow. The goal is to see if this combination can help control the cancer better.
This trial studies an experimental cell therapy called NK510 for people with advanced stomach or colorectal cancer that has not responded to standard treatments. The therapy uses natural killer cells, a type of immune cell, to attack the cancer. It may help slow or stop the cancer's growth.
This trial tests a new immune cell therapy called NK521 for people with advanced solid tumors like liver or ovarian cancer that have not responded to standard treatment. The therapy may be given as an infusion or into the belly (for those with fluid buildup containing cancer cells).
This trial tests whether adding natural killer (NK) cell therapy to standard chemotherapy and a PD-1 inhibitor (a type of immunotherapy) before surgery can help shrink early-stage non-small cell lung cancer and improve outcomes. The goal is to see if this combination is safe and effective.
This trial tests a new treatment using natural killer (NK) cells, a type of immune cell, to fight advanced solid tumors. It may be an option if standard treatments have stopped working or are not available.
This trial tests a new treatment that combines a drug called SYS6010 with an immunotherapy (Enlonstobart) compared to the usual immunotherapy plus chemo for advanced lung cancer. The goal is to see if this combo works better and helps people with PD-L1 positive lung cancer live longer and feel better.
Hear when a new NSCLC trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.